A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.
In addition, findings from the retrospective clinical case series suggested the biomarker test may detect disease recurrence earlier than imaging or other surveillance methods, allowing clinicians to personalize treatment faster for patients whose cancer returns.
«We believe that tumor tissue modified viral [TTMV]-HPV DNA testing should be incorporated into surveillance guidelines